David A Margolis
Overview
Explore the profile of David A Margolis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
2009
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Swindells S, Andrade-Villanueva J, Richmond G, Rizzardini G, Baumgarten A, Masia M, et al.
N Engl J Med
. 2020 Mar;
382(12):1112-1123.
PMID: 32130809
Background: Simplified regimens for the treatment of human immunodeficiency virus type 1 (HIV-1) infection may increase patient satisfaction and facilitate adherence. Methods: In this phase 3, open-label, multicenter, noninferiority trial...
12.
Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, Pokrovsky V, Overton E, Girard P, et al.
N Engl J Med
. 2020 Mar;
382(12):1124-1135.
PMID: 32130806
Background: Long-acting injectable regimens may simplify therapy for patients with human immunodeficiency virus type 1 (HIV-1) infection. Methods: We conducted a phase 3, randomized, open-label trial in which adults with...
13.
Seif A, Li Y, Monos D, Heidemann S, Aplenc R, Barrett D, et al.
Biol Blood Marrow Transplant
. 2019 Nov;
26(3):493-501.
PMID: 31765697
Most children who may benefit from stem cell transplantation lack a matched related donor. Alternative donor transplantations with an unrelated donor (URD) or a partially matched related donor (PMRD) carry...
14.
DAmico R, Margolis D
Curr Opin HIV AIDS
. 2019 Nov;
15(1):13-18.
PMID: 31764197
Purpose Of Review: Long-acting formulations of antiretrovirals have the potential to reshape the treatment paradigm for HIV infection. Emerging evidence demonstrates efficacy and safety of two drug regimens for the...
15.
Liberio N, Robinson H, Nugent M, Simpson P, Margolis D, Malarkannan S, et al.
Pediatr Blood Cancer
. 2019 Aug;
66(11):e27950.
PMID: 31368194
Background: Donor lymphocyte infusion (DLI) is often used to treat leukemic relapse after hematopoietic cell transplantation (HCT). However, the relationship between outcomes and distinct DLI cellular composition has not been...
16.
Landovitz R, Zangeneh S, Chau G, Grinsztejn B, Eron J, Dawood H, et al.
Clin Infect Dis
. 2019 May;
70(2):319-322.
PMID: 31125395
Studies in human immunodeficiency virus (HIV)-infected individuals suggest excess weight gain with integrase inhibitor-based antiretroviral therapy. The HIV Prevention Trials Network Study 077 evaluated changes in weight and fasting metabolic...
17.
Murray M, Markowitz M, Frank I, Grant R, Mayer K, Hudson K, et al.
HIV Clin Trials
. 2018 Nov;
19(4):129-138.
PMID: 30445896
Background: Cabotegravir (GSK1265744) is an integrase strand transfer inhibitor in development as a long-acting (LA) intramuscular injectable suspension for HIV-1 pre-exposure prophylaxis (PrEP). Objective: We report participant outcomes from the...
18.
Margolis D, Gonzalez-Garcia J, Stellbrink H, Eron J, Yazdanpanah Y, Podzamczer D, et al.
Lancet
. 2017 Jul;
390(10101):1499-1510.
PMID: 28750935
Background: Cabotegravir and rilpivirine are antiretroviral drugs in development as long-acting injectable formulations. The LATTE-2 study evaluated long-acting cabotegravir plus rilpivirine for maintenance of HIV-1 viral suppression through 96 weeks....
19.
Burroughs L, Shimamura A, Talano J, Domm J, Baker K, Delaney C, et al.
Biol Blood Marrow Transplant
. 2017 Jun;
23(10):1669-1677.
PMID: 28602958
Hematopoietic cell transplantation (HCT) is effective in the treatment of inherited marrow failure disorders and other nonmalignant diseases. Conventional myeloablative conditioning regimens have been associated with high transplant-related mortality, particularly...
20.
Markowitz M, Frank I, Grant R, Mayer K, Elion R, Goldstein D, et al.
Lancet HIV
. 2017 May;
4(8):e331-e340.
PMID: 28546090
Background: Cabotegravir (GSK1265744) is an HIV-1 integrase strand transfer inhibitor with potent antiviral activity and a long half-life when administered by injection that prevented simian-HIV infection upon repeat intrarectal challenge...